Immunosuppressive treatments can reduce the risk of disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who test…
Articles by Marisa Horak, MS
Researchers have identified a mechanism by which the adult brain can replace astrocytes, the neuron-supporting cells in the brain that…
A global clinical trial testing Ultomiris (ravulizumab-cwvz) in adults with neuromyelitis optica spectrum disorder (NMOSD) found that the…
Ultomiris (ravulizumab-cwvz) and Soliris (eculizumab), two approved treatments for neuromyelitis optica spectrum disorder (NMOSD), may work better…
Even if they don’t have disease relapses, people with neuromyelitis optica spectrum disorder (NMOSD) tend to experience abnormal atrophy,…
Most documented safety issues reported during Enspryng (satralizumab-mwge) treatment for neuromyelitis optica spectrum disorder (NMOSD) in a real-world…
Treatment with Enspryng (satralizumab) for more than two years was shown to prevent relapses in most people with…
March is NMOSD Awareness Month, and advocates around the world are working to educate others and raise the profile of…
Nearly a third of people with neuromyelitis optica spectrum disorder (NMOSD) may have cognitive impairment, especially in the areas…
People with neuromyelitis optica spectrum disorder (NMOSD) who are negative for typical disease-driving antibodies show several differences in clinical…